Search Results
Mar 23, 2026, 14:54 ET Netenrich Launches Cyber Risk Operations
failures.Netenrich leverages Agentic AI to bridge the gap between risk and operations, accelerating the evolution toward Autonomous Security Operations (ASO) through the Resolution Intelligence Cloud's outcome-driven approach, enabling enterprises to not just feel safe, but to be prepared. Visit our website
More news about: Netenrich
Mar 23, 2026, 09:24 ET PRE Security Unveils Breakthrough Version 3.3 and Earns Top Industry Awards Ahead of RSA Conference 2026
Company introduces SignalGate™ AI data fabric and fully agentic natural language Autonomous Security Operator "ASO;" recognized for Best AI SecOps and Best Cybersecurity Startup by 2026 Cybersecurity Excellence AwardsSAN JOSE, Calif., March
More news about: PRE Security
Mar 20, 2026, 09:05 ET Academy Sports + Outdoors Launches New Tiered myAcademy® Rewards Credit Card and Enhanced Loyalty Program Designed to Help Families Save More and Have More Fun
Academy Sports + Outdoors ("Academy") (Nasdaq: ASO), a leading full-line sporting goods and outdoor recreation retailer, today announced the national rollout of the new myAcademy Rewards Mastercard®
More news about: Academy, Ltd. d/b/a Academy Sports + Outdoors
Mar 12, 2026, 09:05 ET Academy Sports + Outdoors Launches Five-Week Work Boot Campaign Championing Access to Trusted Brands and Strong Value
Nasdaq: ASO) is elevating its work boot shopping experience with five weeks of exclusive savings designed for every trade. From Sunday, March 15 to Saturday, April
More news about: Academy, Ltd. d/b/a Academy Sports + Outdoors
Mar 11, 2026, 09:05 ET Academy Sports + Outdoors Increases Year-over-Year Donation to St. Jude Children's Research Hospital® to More Than $575,000
Academy Sports + Outdoors ("Academy") (Nasdaq: ASO) announced an increased year‑over‑year donation of more than $575,000 to
More news about: Academy, Ltd. d/b/a Academy Sports + Outdoors
Mar 10, 2026, 09:05 ET Academy Sports + Outdoors Grows Retail Footprint with Two New Locations in Ohio and Oklahoma
Nasdaq: ASO), a leading full-line sporting goods and outdoor recreation retailer, is excited to announce it will open two new locations in
More news about: Academy, Ltd. d/b/a Academy Sports + Outdoors
Mar 06, 2026, 09:05 ET Academy Sports + Outdoors Increases Quarterly Cash Dividend
Academy Sports and Outdoors, Inc. (the "Company" or "Academy") (Nasdaq: ASO) announced today that on March 5, 2026, its Board of Directors declared a quarterly cash dividend of $0.15 per share of the Company's common stock with
More news about: Academy, Ltd. d/b/a Academy Sports + Outdoors
Mar 05, 2026, 09:05 ET Celebrate Academy Sports + Outdoors Run Month with Exclusive Deals, Promotions and Gifts for Runners of All Experience Levels
Academy Sports + Outdoors ("Academy" or the "Company") (Nasdaq: ASO) announced today that during Academy Run Month, a month‑long celebration taking place Sunday, March 1, through Tuesday, March 31, it will equip runners
More news about: Academy, Ltd. d/b/a Academy Sports + Outdoors
Mar 05, 2026, 08:00 ET Therna Announces Collaboration with Charles River to Advance Single-Patient Personalized RNA Therapeutics
Lead mRNA program targeting an ultra-rare lung fibrosis and lead ASO program for ultra-rare central nervous system disorderCollaboration unveiled at the Personalized Medicine World ConferenceSAN FRANCISCO,
More news about: Therna Biosciences
Mar 04, 2026, 16:11 ET AppTweak Launches AI Agents to Scale ASO and Apple Ads Performance
marketers the confidence to act quickly on insights they can trust."The launch introduces ASO Agent, Reviews Agent, and Reporting Agent, expanding AppTweak's AI offering across ASO analysis, app store reviews, and performance reporting. It builds on the release of Ad Agent,
More news about: AppTweak
Mar 04, 2026, 09:05 ET Academy Sports + Outdoors Hits It Out of the Park with Grand Slam Deals on Top Youth Baseball, Softball Brands
Nasdaq: ASO), a leading full-line sporting goods and outdoor recreation retailer, is excited to announce the return of its
More news about: Academy, Ltd. d/b/a Academy Sports + Outdoors
Mar 03, 2026, 09:05 ET Academy Sports + Outdoors Announces Fourth Quarter and Fiscal 2025 Results Conference Call
Nasdaq: ASO), a leading full-line sporting goods and outdoor recreation retailer, plans to release its fourth quarter and fiscal 2025 financial results before the
More news about: Academy, Ltd. d/b/a Academy Sports + Outdoors
Mar 03, 2026, 08:41 ET As AI Agents Replace Search Engines, Capxel Introduces AI Search Optimization -- A New Category of Brand Intelligence
majority of brands are invisible to them."Every company has an SEO strategy. Almost none have an ASO strategy," said Dominick Luna, Co-Founder / President of Capxel, who originated the ASO framework. "The brands that show up when an AI agent answers 'What's the best [product] for [use case]?'
More news about: Capxel
Mar 03, 2026, 07:00 ET SpliSense Granted EMA EARLY PRIME Designation for SPL84 in Cystic Fibrosis
ppFEV1 compared with placebo was 10. These data represent the first evidence of potential clinical benefit for an inhaled antisense oligonucleotide (ASO) therapy in a pulmonary disease.About PRIME designationPRIME is granted to medicines that may offer a major therapeutic advantage
More news about: Splisense
Feb 25, 2026, 08:37 ET Capxel Launches LLM-LD, the First Open Standard for Making Websites Readable by AI Agents
AI Search Optimization (ASO) — a discipline conceived by Co-Founder / President Dominick Luna that focuses on structuring brand content for discoverability by AI agents rather
More news about: Capxel
Feb 24, 2026, 16:10 ET Evolent Announces Fourth Quarter 2025 Results and Full Year 2025 Results
Performance Suite Lives on Platform are calculated by summing monthly members covered for specialty care services for contracts not under ASO arrangements, plus members managed by Complex Care in capitation arrangements and divided by the number of months in the period. Specialty Technology
More news about: Evolent Health, Inc.
Feb 24, 2026, 08:30 ET Therna Biosciences Appoints Biotech Veteran Devyn Smith, Ph.D., to Board of Directors and Expands Strategic and Scientific Advisory Leadership
stability, immune evasion, and tissue-specific expression. The platform also efficiently identifies optimal target sites within mRNA for maximally effective ASO/siRNA design. Therna's technology allows gene expression to be upregulated, downregulated, or finely tuned, enabling broad applications across a range
More news about: Therna Biosciences
Jan 13, 2026, 09:09 ET n-Lorem and EspeRare announce European collaboration to expand access to individualized ASO Therapies for Rare Genetic Diseases
will co-develop fit-for-purpose access frameworks for n-Lorem's ASO therapies built upon scientific rigor, patient safety, and robust ethical oversight.n-Lorem has led the discovery and development of personalized experimental ASO medicines and currently treats the largest number of nano-rare patients
More news about: EspeRare Foundation
Jan 13, 2026, 03:00 ET n-Lorem und EspeRare kündigen europäische Zusammenarbeit zur Erweiterung des Zugangs zu individualisierten ASO-Therapien für seltene genetische Erkrankungen an
Entwicklung individualisierter und experimenteller ASO-Therapien und behandelt derzeit weltweit die größte Anzahl von Patienten mit seltenen Nano-Erkrankungen. Der industrialisierte Ansatz basiert auf fundierter wissenschaftlicher Expertise, umfassender Expertise in ASO-Technologien und langjähriger Erfahrung in
More news about: EspeRare Foundation
Jan 13, 2026, 03:00 ET n-Lorem and EspeRare annoncent une collaboration européenne pour élargir l'accès aux thérapies ASO individualisées pour les maladies génétiques rares
le développement de traitements ASO individualisés et expérimentaux, et traite aujourd'hui le plus grand nombre de patients nano-rares dans le monde. Son approche industrialisée repose sur une expertise scientifique approfondie, une maîtrise des technologies ASO, ainsi qu'une vaste expérience dans
More news about: EspeRare Foundation
Jan 12, 2026, 13:43 ET n-Lorem and EspeRare announce European collaboration to expand access to individualized ASO Therapies for Rare Genetic Diseases
will co-develop fit-for-purpose access frameworks for n-Lorem's ASO therapies built upon scientific rigor, patient safety, and robust ethical oversight. n-Lorem has led the discovery and development of personalized experimental ASO medicines and currently treats the largest number of nano-rare
More news about: EspeRare Foundation
Jan 06, 2026, 13:27 ET Aperture Therapeutics Announces First-In-Class MMP9 Antisense Oligonucleotide Program for ALS
precision medicines for neurodegenerative diseases, today announced the advancement of its matrix metalloproteinase-9 (MMP9) antisense oligonucleotide (ASO) program, APRTX-003, for the treatment of Amyotrophic Lateral Sclerosis (ALS). The program targets chronic neuroinflammation and neurodegeneration,
More news about: Aperture Therapeutics
Dec 22, 2025, 05:07 ET AusperBio Completes Patient Enrollment in Phase III AUSHINE Study of AHB-137 for Chronic Hepatitis B
proprietary Med-Oligo™ ASO platform which has been shown to substantially enhance the current ASO therapeutics, through novel insights into ASO design. Combining efficient targeted delivery conjugation technologies, the modular Med-Oligo™ platform empowers ASO therapeutics to treat a broad
More news about: AusperBio Therapeutics Inc.
Dec 19, 2025, 09:05 ET Academy Sports + Outdoors Gifts More Than $135,000 to Local Families this Holiday Season
Nasdaq: ASO) is also focused on making a positive impact in local communities. Throughout the holidays, Academy hosted more than 40 giving events, including at
More news about: Academy, Ltd. d/b/a Academy Sports + Outdoors
Dec 17, 2025, 06:50 ET Protalix Biotherapeutics and Secarna Pharmaceuticals Enter into Collaboration and Option Agreement
collaboration and option agreement. Under this agreement, the companies have agreed to partner in the discovery of novel antisense oligonucleotide (ASO) therapies against multiple targets for rare renal indications.
More news about: Protalix BioTherapeutics, Inc.; Secarna Pharmaceuticals